These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31200710)

  • 1. Medium-term health-related quality of life in patients with pulmonary arterial hypertension treated with goal-oriented sequential combination therapy based on exercise capacity.
    Hirashiki A; Adachi S; Okumura N; Nakano Y; Shimokata S; Shimizu A; Arai H; Toba K; Murohara T; Kondo T
    Health Qual Life Outcomes; 2019 Jun; 17(1):103. PubMed ID: 31200710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension.
    Hirashiki A; Adachi S; Nakano Y; Kamimura Y; Shimokata S; Takeshita K; Shimizu A; Toba K; Murohara T; Kondo T
    Pulm Circ; 2017; 7(2):448-454. PubMed ID: 28597753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.
    Mehta S; Sastry BKS; Souza R; Torbicki A; Ghofrani HA; Channick RN; Delcroix M; Pulido T; Simonneau G; Wlodarczyk J; Rubin LJ; Jansa P; Hunsche E; Galiè N; Perchenet L; Sitbon O
    Chest; 2017 Jan; 151(1):106-118. PubMed ID: 27671974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life as a prognostic marker in pulmonary arterial hypertension.
    Fernandes CJ; Martins BC; Jardim CV; Ciconelli RM; Morinaga LK; Breda AP; Hoette S; Souza R
    Health Qual Life Outcomes; 2014 Aug; 12():130. PubMed ID: 25176512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study.
    Gerhardt F; Dumitrescu D; Gärtner C; Beccard R; Viethen T; Kramer T; Baldus S; Hellmich M; Schönau E; Rosenkranz S
    Heart; 2017 Apr; 103(8):592-598. PubMed ID: 28100544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO2.
    Hirashiki A; Adachi S; Nakano Y; Kono Y; Shimazu S; Shimizu S; Morimoto R; Okumura T; Takeshita K; Yamada S; Murohara T; Kondo T
    Life Sci; 2014 Nov; 118(2):397-403. PubMed ID: 24641953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.
    Lammi MR; Mathai SC; Saketkoo LA; Domsic RT; Bojanowski C; Furst DE; Steen VD;
    Arthritis Rheumatol; 2016 Mar; 68(3):740-8. PubMed ID: 26479414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Portopulmonary hypertension in the current era of pulmonary hypertension management.
    Savale L; Guimas M; Ebstein N; Fertin M; Jevnikar M; Renard S; Horeau-Langlard D; Tromeur C; Chabanne C; Prevot G; Chaouat A; Moceri P; Artaud-Macari É; Degano B; Tresorier R; Boissin C; Bouvaist H; Simon AC; Riou M; Favrolt N; Palat S; Bourlier D; Magro P; Cottin V; Bergot E; Lamblin N; Jaïs X; Coilly A; Durand F; Francoz C; Conti F; Hervé P; Simonneau G; Montani D; Duclos-Vallée JC; Samuel D; Humbert M; De Groote P; Sitbon O
    J Hepatol; 2020 Jul; 73(1):130-139. PubMed ID: 32145258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Goal-Oriented Sequential Combination Therapy Evaluated Using Cardiopulmonary Exercise Parameters for the Treatment of Newly Diagnosed Pulmonary Arterial Hypertension　- Goal-Oriented Therapy Evaluated by Cardiopulmonary Exercise Testing for Pulmonary Arterial Hypertension (GOOD EYE).
    Hirashiki A; Kondo T; Adachi S; Nakano Y; Kamimura Y; Shimokata S; Okumura N; Shimizu A; Washimi Y; Arai H; Murohara T;
    Circ Rep; 2019 Jun; 1(7):303-311. PubMed ID: 33693154
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of tight association between quality of life and exercise capacity in pulmonary arterial hypertension.
    Cícero C; Franchi SM; Barreto AC; Lopes AA
    Arq Bras Cardiol; 2012 Oct; 99(4):876-85. PubMed ID: 22936028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation].
    Kaemmerer H; Gorenflo M; Hoeper M; Huscher D; Ewert P; Pittrow D
    Dtsch Med Wochenschr; 2013 Jun; 138(23):1247-52. PubMed ID: 23720182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
    BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
    Jansa P; Pulido T
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):1-11. PubMed ID: 29280064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
    Hansmann G; Apitz C
    Heart; 2016 May; 102 Suppl 2():ii67-85. PubMed ID: 27053700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.
    Gu S; Hu H; Dong H
    Pharmacoeconomics; 2016 Aug; 34(8):751-70. PubMed ID: 26951248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary arterial hypertension: a current review of pharmacological management.
    Sahni S; Ojrzanowski M; Majewski S; Talwar A
    Pneumonol Alergol Pol; 2016; 84(1):47-61. PubMed ID: 26693827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.